In a report released on January 24, Conor McNamara from RBC Capital maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $6.47.
According to TipRanks, McNamara is an analyst with an average return of -10.0% and a 38.81% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Illumina, QuidelOrtho, and SOPHiA GENETICS.
Maravai Lifesciences Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $8.71.
See Insiders’ Hot Stocks on TipRanks >>
Based on Maravai Lifesciences Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $66.87 million and a GAAP net loss of $6.46 million. In comparison, last year the company earned a revenue of $191.26 million and had a net profit of $44.47 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Maravai Lifesciences Holdings (MRVI) Company Description:
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company’s segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers’ research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Read More on MRVI:
Click Here to Read the Full Original Article at TipRanks Financial Blog…
